# EDGAR Filing Document

**Accession Number:** 0001787123
**File Stem:** 0001477932-23-000247
**Filing Date:** 2023-1
**Character Count:** 38669
**Document Hash:** 81b7375163b5a913ba0896b0f5d2360c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-23-000247.hdr.sgml**: 20230113

**ACCESSION NUMBER**: 0001477932-23-000247

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 38

**CONFORMED PERIOD OF REPORT**: 20221130

**FILED AS OF DATE**: 20230113

**DATE AS OF CHANGE**: 20230113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QLY Biotech Group Corp.
- **CENTRAL INDEX KEY:** 0001787123
- **STANDARD INDUSTRIAL CLASSIFICATION:** TRANSPORTATION SERVICES [4700]
- **IRS NUMBER:** 981448750
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-234137
- **FILM NUMBER:** 23528285

**BUSINESS ADDRESS:**
- **STREET 1:** CARRETERA TURISTICA, LUPERON, 12TH KM
- **STREET 2:** NO. 7, GRAND PARADA
- **CITY:** PUERTO PLATA
- **STATE:** G8
- **ZIP:** 57000
- **BUSINESS PHONE:** 829-947-5251

**MAIL ADDRESS:**
- **STREET 1:** CARRETERA TURISTICA, LUPERON, 12TH KM
- **STREET 2:** NO. 7, GRAND PARADA
- **CITY:** PUERTO PLATA
- **STATE:** G8
- **ZIP:** 57000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Azar International Corp.
- **DATE OF NAME CHANGE:** 20190903

?xml version="1.0" encoding="utf-8"?lqly_10q.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☒&nbsp;&nbsp;&nbsp;&nbsp; **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Quarterly Period Ended November 30, 2022**

**or**

☐&nbsp;&nbsp;&nbsp;&nbsp; **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _________ to _________**

**Commission File Number 333-234137**

---

| |
|:---|
| **QLY BIOTECH GROUP CORP.** |
| (Exact name of registrant issuer as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **7999** | **98-1448750** |
| (State or Other jurisdiction of<br>incorporation or organization) | (Primary Standard Industrial<br>Classification Number)  | (I.R.S. Employer<br>Identification No.) |

---

**<u>5348 VEGAS DRIVE, LAS VEGAS, Nevada 89108</u>**

(Address of principal executive offices, including zip code)

**<u>(+86) 18678961296</u>**

Registrant's phone number, including area code

Securities registered pursuant to Section 12(b) of the Act: **None**

Securities registered pursuant to Section 12(g) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Common stock, $.001 par value | LQLY | N/A |

---

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐&nbsp;&nbsp;&nbsp;&nbsp; No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☐&nbsp;&nbsp;&nbsp;&nbsp; No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒&nbsp;&nbsp;&nbsp;&nbsp; NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit and post such files).

Yes ☒&nbsp;&nbsp;&nbsp;&nbsp; NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" or an "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐&nbsp;&nbsp;&nbsp;&nbsp; No ☒

The aggregate market value of the voting stock and non-voting common equity held by non-affiliates of the registrant as of January 13, 2023, was approximately $0.9 million.

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

---

| | |
|:---|:---|
| **Class** | **Outstanding at January 13, 2023** |
| Common Stock, $.001 par value | 3895000 |

---

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| **[PART I](#p1)** | **[FINANCIAL INFORMATION](#p1)** |  |
| [ITEM 1.](#p1i1) | [FINANCIAL STATEMENTS:](#p1i1) | F-1 |
|  | [Condensed Balance Sheets as of November 30, 2022 and August 31, 2022 (unaudited)](#bs) | F-1 |
|  | [Condensed Statements of Operations and Comprehensive Loss for the three months ended November 30, 2022 and 2021 (unaudited)](#soo) | F-2 |
|  | [Condensed Statement of Changes in Stockholders' Deficit for the three months ended November 30, 2022 and 2021 (unaudited)](#deficit) | F-3 |
|  | [Condensed Statements of Cash Flows for the three months ended November 30, 2022 and 2021(unaudited)](#cf) | F-4 |
|  | [Notes to the Condensed Financial Statements (unaudited)](#notes) | F-5 |
| [ITEM 2.](#p1i2) | [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#p1i2) | 2 |
| [ITEM 3.](#p1i3) | [QUANTITATIVE AND QUALITATIVED IS CLOSURES ABOUT MARKET RISK](#p1i3) | 4 |
| [ITEM 4.](#p1i4) | [CONTROLS AND PROCEDURES](#p1i4) | 4 |
| **[PART II](#p2)** | **[OTHER INFORMATION](#p2)** |  |
| [ITEM 1](#p2i1) | [LEGAL PROCEEDINGS](#p2i1) | 5 |
| [ITEM 2](#p2i2) | [UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS](#p2i2) | 5 |
| [ITEM 3](#p2i3) | [DEFAULTS UPON SENIOR SECURITIES](#p2i3) | 5 |
| [ITEM 4](#p2i4) | [MINE SAFETY DISCLOSURES](#p2i4) | 5 |
| [ITEM 5](#p2i5) | [OTHER INFORMATION](#p2i5) | 5 |
| [ITEM 6](#p2i6) | [EXHIBITS](#p2i6) | 6 |
|  | [SIGNATURES](#sig) | 7 |

---

---

| |
|:---|
| 1 |
| *[**Table of Contents**](#toc)* |

---

**PART I – FINANCIAL INFORMATION**

**Item 1. Financial statements**

**QLY BIOTECH GROUP CORP.**

**CONDENSED BALANCE SHEETS**

**AS OF NOVEMBER 30, 2022 AND AUGUST 31, 2022 (Unaudited)**

**(Currency expressed in United States Dollars ("US$"), except for number of shares)**

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **November 30, 2022** | **August 31, 2022** |
| **ASSETS** |  |  |
| **TOTAL ASSETS** | $- | $- |
| **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |
| CURRENT LIABILITIES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | $3500 | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount due to a director | 4548 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 8048 | - |
| **TOTAL LIABILITIES** | $8048 | $- |
| STOCKHOLDERS' DEFICIT |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value, 1,000,000,000 shares authorized, 3,895,000 shares issued and outstanding as of November 30, 2022 and August 31, 2022, respectively | $3895 | $3895 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 47150 | 46030 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (59093) | (49925) |
| **TOTAL STOCKHOLDERS' DEFICIT** | (8048) | - |
| **TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT** | $- | $- |

---

See accompanying notes to the unaudited condensed financial statements.

---

| |
|:---|
| F-1 |
| *[**Table of Contents**](#toc)* |

---

**QLY BIOTECH GROUP CORP.**

**CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

**FOR THE THREE MONTHS ENDED NOVEMBER 30, 2022 AND 2021 (Unaudited)**

**(Currency expressed in United States Dollars ("US$"), except for number of shares)**

---

| | | |
|:---|:---|:---|
|  | **For three months ended November 30,** | **For three months ended November 30,** |
|  | **2022** | **2021** |
| REVENUES | $- | $- |
| COSTS OF REVENUES | - | - |
| GROSS INCOME |  |  |
| GENERAL & ADMINISTRATIVE EXPENSES | 9168 | 4212 |
| LOSS BEFORE INCOME TAX | (9168) | (4212) |
| INCOME TAX EXPENSES | - | - |
| NET LOSS | $(9168) | $(4212) |
| Other comprehensive gain (loss): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange adjustment gain (loss) | - | - |
| COMPREHENSIVE LOSS | $(9168) | $(4212) |
| Net loss per share - Basic and diluted | $(0.00) | $(0.00) |
| Weighted average number of common shares outstanding – Basic and diluted | 3895000 | 3895000 |

---

See accompanying notes to the unaudited condensed financial statements.

---

| |
|:---|
| F-2 |
| *[**Table of Contents**](#toc)* |

---

**QLY BIOTECH GROUP CORP.**

**CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT**

**FOR THE THREE MONTHS ENDED NOVEMBER 30, 2022 AND 2021 (Unaudited)**

**(Currency expressed in United States Dollars ("US$"), except for number of shares)**

**For the three months ended November 30, 2022**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **COMMON STOCK** | **COMMON STOCK** | | | |
|  | **Number of**<br>**shares** | **Amount** | **ADDITIONAL**<br>**PAID-IN**<br>**CAPITAL** | <br>**ACCUMULATED**<br>**DEFICIT** | **TOTAL**<br>**STOCKHOLDER DEFICT** |
| Balance as of September 1, 2022  | 3895000 | $3895 | $46030 | $(49925) | $- |
| Satisfaction of amount due to current shareholder on November 30, 2022 |  |  | 1120 |  | 1120 |
| Net loss | - | - | - | (9168) | (9168) |
| Balance as of November 30, 2022  | 3895000 | $3895 | $47150 | $(59093) | $(8048) |

---

**For the three months ended November 30, 2021**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **COMMON STOCK** | **COMMON STOCK** | | | |
|  | **Number of**<br>**shares** | **Amount** | **ADDITIONAL**<br>**PAID-IN**<br>**CAPITAL** | <br>**ACCUMULATED**<br>**DEFICIT** | **TOTAL**<br>**STOCKHOLDER DEFICT** |
| Balance as of September 1, 2021 | 3895000 | $3895 | $25955 | $(35813) | $(5963) |
| Net loss | - | - | - | (4212) | (4212) |
| Balance as of November 30, 2021 | 3895000 | $3895 | $25955 | $(40025) | $(10175) |

---

See accompanying notes to the unaudited condensed financial statements.

---

| |
|:---|
| F-3 |
| *[**Table of Contents**](#toc)* |

---

**QLY BIOTECH GROUP CORP.**

**CONDENSED STATEMENTS OF CASH FLOWS**

**FOR THE THREE MONTHS ENDED NOVEMBER 30, 2022 AND 2021 (Unaudited)**

**(Currency expressed in United States Dollars ("US$"), except for number of shares)**

---

| | | |
|:---|:---|:---|
|  | **For the three months ended November 30,** | **For the three months ended November 30,** |
|  | **2022** | **2021** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |
| Net loss | $(9168) | $(4212) |
| Adjustments to reconcile net loss to net cash used in operating activities |  |  |
| Amortization cost and depreciation |  | 428 |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable |  | (1025) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities  | 3500 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in operating activities** | (5668) | (4809) |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds of loan from former shareholder |  | 800 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds of loan from current shareholder | 5668 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash generated from financing activities** | 5668 | 800 |
| Effect of exchange rate changes on cash and cash equivalents | - | - |
| Net change in cash and cash equivalents |  | (4009) |
| Cash and cash equivalents, beginning of year | - | 5169 |
| **CASH AND CASH EQUIVALENTS, END OF YEAR** | $- | $1160 |
| **SUPPLEMENTAL CASH FLOWS INFORMATION** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes paid | $- | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest paid | $- | $- |
| **NON-CASH INVESTMENT AND FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Satisfaction of amount due to current shareholder on November 30, 2022 | $1120 | $- |

---

See accompanying notes to the unaudited condensed financial statements.

---

| |
|:---|
| F-4 |
| *[**Table of Contents**](#toc)* |

---

**QLY BIOTECH GROUP CORP.**

**NOTES TO CONDENSED FINANCIAL STATEMENTS**

**FOR THE THREE MONTHS ENDED NOVEMBER 30, 2022 (Unaudited)**

**(Currency expressed in United States Dollars ("US$"), except for number of shares)**

**NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND**

QLY Biotech Group Corp., a Nevada corporation ("the Company" or "QLY") was incorporated under the laws of the State of Nevada on September 20, 2018.

The Company was used to engaged in the tourism. The company used to organize individual and group sailing tours in the Dominican Republic. Services and itineraries were used to be provide by our company include custom packages according to the client's specifications. And we used to develop and offer our own sailing tours in the North part of Dominican Republic as well as third-party suppliers.

On July 8, 2022, as a result of a private transactions, 3,000,000 shares of common stock, $0.001 par value per share (the "Shares") of QLY Biotech Group Corp. (Former name: Azar International Corp.)., were transferred from Hilario Lopez Vargas to Lixue Yang. As a result, Lixue Yang became holders of approximately 77% of the voting rights of the issued and outstanding share capital of the Company and became the controlling shareholder. The consideration paid for the Shares was $350,000. The source of the cash consideration for the Shares was personal funds of Lixue Yang. In connection with the transaction, Hilario Lopez Vargas released the Company from all debts owed to him, and the Company agreed to assign the Computer and Designer (that were acquired by the Company on September 30, 2019 and November 1, 2019, respectively) to him.

On July 8, 2022, the existing director and officer resigned immediately. Accordingly, Hilario Lopez Vargas, serving as a director and an officer, ceased to be the Company's Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary and a Director. At the effective date of the transfer, Lixue Yang consented to act as the new Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary and a Director of the Company.

**NOTE 2 - GOING CONCERN UNCERTAINTIES**

As of November 30, 2022, the Company suffered an accumulated deficit of $59,093 and incurred a net loss of $9,168. The continuation of the Company as a going concern through November 30, 2022 is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide the additional cash to meet the Company's obligations as they become due.

These and other factors raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result in the Company not being able to continue as a going concern.

**NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The accompanying unaudited condensed financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying financial statements and notes.

● Basis of presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America. The Company's fiscal year end is August 31. The Company's financial statements are presented in U.S. dollars.

● Use of estimates

In preparing these condensed financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the periods reported. Actual results may differ from these estimates.

● Cash and cash equivalents

The company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

---

| |
|:---|
| F-5 |
| *[**Table of Contents**](#toc)* |

---

**QLY BIOTECH GROUP CORP.**

**NOTES TO CONDENSED FINANCIAL STATEMENTS**

**FOR THE THREE MONTHS ENDED NOVEMBER 30, 2022 (Unaudited)**

**(Currency expressed in United States Dollars ("US$"), except for number of shares)**

● Property, plant and equipment

Property, plant and equipment are carried at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line method. Estimated useful lives of the property and equipment are as follows:

---

| | |
|:---|:---|
| Office equipment  | 3 years |

---

The cost of maintenance and repairs is charged to expenses as incurred, whereas significant renewals and betterments are capitalized.

● Intangible assets, net

Intangible assets with definite lives are stated at cost less accumulated amortization.

Amortization is calculated on the straight-line basis over the following estimated useful lives:

---

| | |
|:---|:---|
| Website | 3 years |

---

● Revenue recognition 

The Company assesses and follows the guidance of ASC 606, revenue from contracts with customers is recognized using the following five steps:

1. Identify the contract(s) with a customer;

2. Identify the performance obligations in the contract;

3. Determine the transaction price;

4. Allocate the transaction price to the performance obligations in the contract; and

5. Recognize revenue when (or as) the entity satisfies a performance obligation.

The Company had generated zero revenue during the three months ended November 30, 2022 and 2021, respectively.

● Income taxes

The Company followed the liability method of accounting for income taxes in accordance with ASC 740, Income Taxes, or ASC 740. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Company recorded a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.

The Company accounted for uncertainties in income taxes in accordance with ASC 740. Interest and penalties related to unrecognizable tax benefit recognized in accordance with ASC 740 are classified in the statements of comprehensive loss as income tax expense.

● Earnings per share

The Company computes earnings per share ("EPS") in accordance with ASC Topic 260, "Earnings per share". Basic EPS is measured as the income or loss available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options, and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Any potential common shares in 2022 and 2021 that have an anti-dilutive effect (i.e. those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

---

| |
|:---|
| F-6 |
| *[**Table of Contents**](#toc)* |

---

**QLY BIOTECH GROUP CORP.**

**NOTES TO CONDENSED FINANCIAL STATEMENTS**

**FOR THE THREE MONTHS ENDED NOVEMBER 30, 2022 (Unaudited)**

**(Currency expressed in United States Dollars ("US$"), except for number of shares)**

● Related party transaction

A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

Transactions involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm's-length transactions unless such representations can be substantiated.

● Recent accounting pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

**NOTE 4 – ACCRUED LIABILITIES**

As of November 30, 2022, the balance of accrued liabilities was $3,500 that including the audit fee and stock agency expenses. As of August 31, 2022, the balance of accrued liabilities was $0.

**NOTE 5 - AMOUNT DUE TO A DIRECTOR**

As of November 30, 2022 and August 31, 2022, the director of the Company, Mr. Lixue Yang, advanced $4,548 and $0 to the Company, respectively, which is unsecured, interest-free with no fixed payment term, for working capital purpose.

**NOTE 6 – COMMON STOCK**

As of November 30, 2022 and August 31, 2022, the Company has 1,000,000,000 share authorized, 3,895,000 shares issued and outstanding, respectively. There are no shares of preferred stock issued and outstanding.

**NOTE 7 – ADDITIONAL PAID-IN CAPITAL – CAPITAL CONTRIBUTION**

As of November 30, 2022 and August 31, 2022, the Company has a total additional paid-in capital - capital contribution balance of $47,150 and $46,030, respectively. Such increase was due to the satisfaction of amount of $1,120 due to current shareholder on November 30, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;

**NOTE 8 – SUBSEQUENT EVENT**

In accordance with ASC Topic 855, "Subsequent Events", which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before condensed financial statements are issued, the Company has evaluated all events or transactions that occurred up to January 13, 2023, the date the financial statements were available to issue. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.

---

| |
|:---|
| F-7 |
| *[**Table of Contents**](#toc)* |

---

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this Report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed below and elsewhere in this Report. Our audited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.*

**Company Overview**

QLY Biotech Group Corp. ("the Company" or "QLY"), was incorporated in the State of Nevada on September 20, 2018. The Company was used to engaged in the tourism. The company used to organize individual and group sailing tours in the Dominican Republic. Services and itineraries were used to be provide by our company include custom packages according to the client's specifications. And we used to develop and offer our own sailing tours in the North part of Dominican Republic as well as third-party suppliers.

The Company has no operations or revenue as of the date of this Report due to the current director had not perform similar service. We are currently in the process of developing a business plan. Management intends to explore and identify viable business opportunities within the U.S. including seeking to acquire a business in a reverse merger. Our ability to effectively identify, develop and implement a viable plan for our business may be hindered by risks and uncertainties which are beyond our control, including without limitation, the continued negative effects of the coronavirus pandemic on the U.S. and global economies.

**Results of Operation**

**For the three months ended November 30, 2022 compared with the three months ended November 30, 2021**

*Revenue*

The Company generated revenue of $0 for the three months ended November 30, 2022 as compared to revenue of $0 for the three months ended November 30, 2021. The management intends to explore and identify business opportunities within the U.S., including a potential acquisition of an operating entity through a reverse merger, asset purchase or similar transaction. Our Chief Executive Officer has experience in business consulting, although no assurances can be given that he can identify and implement a viable business strategy or that any such strategy will result in profits. Our ability to effectively identify, develop and implement a viable plan for our business may be hindered by risks and uncertainties which are beyond our control, including without limitation, the continued negative effects of the coronavirus pandemic on the U.S. and global economies.

*Cost of revenues*

Cost of revenues of $0 and $0 for the three months ended November 30, 2022 and 2021, respectively.

*Operating Expenses*

Operating expenses of $9,168 and $4,212 for the three months ended November 30, 2022 and 2021, that were mainly consist of professional fees such as audit fees, annual list and edgar filing fee etc. Such increase was mainly derived from annual list and stock agency fee.

*Net Loss*

The net loss of $9,168 and $4,212 for the three months ended November 30, 2022 and 2021, respectively. Such increase was mainly derived from annual list and stock agency fee.

*Liquidity and Capital Resources*

As of November 30, 2022 and August 31, 2022, we had working capital deficit of $8,048 and $0, respectively. The increase in working capital deficit was reflected in the accrued liabilities and advanced from director. The Company's net loss of $9,168 and $4,212 for the three months ended November 30, 2022 and 2021, respectively.

*Cash Flow from Operating Activities*

Net cash used in operating activities for the three months ended November 30, 2022 was $5,668 as compared to net cash used in operating activities of $4,809 for the three months ended November 30, 2021, reflecting an increase of $859 on net cash used in operating activities. Such increase was due to the Company incurred a lower net loss in current year.

*Cash Flow from Investing Activities*

Net cash generated from investing activities for the three months ended November 30, 2022 and 2021, was $0 and $0, respectively.

*Cash Flow from Financing Activities*

Net cash generated from financing activities for the three months ended November 30, 2022 was $5,668 as compared to net cash generated from financing activities of $800 for the three months ended November 30, 2021, reflecting an increase of $4,868 on net cash generated from financing activities. Such increase was mainly due to the director that paid the Company's operating expenses on behalf of the Company, such as audit fee, annual list and stock agency fee etc.

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#toc)* |

---

*Credit Facilities*

We do not have any credit facilities or other access to bank credit.

*Contractual Obligations, Commitments and Contingencies*

We currently have three lease agreement in place with respect to office premises in Beijing and Changsha China to commence our business operations.

*Off-balance Sheet Arrangements*

As of November 30, 2022, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

**Item 3 Quantitative and Qualitative Disclosures About Market Risk.**

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

**Item 4 Controls and Procedures.**

**Evaluation of Disclosure Controls and Procedures:**

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of November 30, 2022. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of November 30, 2022, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of November 30, 2022, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

**Changes in Internal Control over Financial Reporting:**

There were no changes in our internal control over financial reporting during the quarter ending November 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#toc)* |

---

**PART II — OTHER INFORMATION**

**Item 1. Legal Proceedings**

We know of no materials, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest adverse to us.

**Item 1A. Risk Factors.**

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information.**

None.

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#toc)* |

---

**ITEM 6. Exhibits**

---

| | |
|:---|:---|
| Exhibit No. | Description |
| [31.1](lqly_ex311.htm) | [Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer\*](lqly_ex311.htm) |
| [32.1](lqly_ex312.htm) | [Section 1350 Certification of principal executive officer \*](lqly_ex312.htm) |
| 101.INS | XBRL Instance Document\* |
| 101.SCH | XBRL Schema Document\* |
| 101.CAL | XBRL Calculation Linkbase Document\* |
| 101.DEF | XBRL Definition Linkbase Document\* |
| 101.LAB | XBRL Label Linkbase Document\* |
| 101.PRE | XBRL Presentation Linkbase Document\* |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\* Filed herewith.

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#toc)* |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | QLY BIOTECH GROUP CORP. | QLY BIOTECH GROUP CORP. |
|  | (Name of Registrant) | (Name of Registrant) |
| Date: January 13, 2023 | By: | ***/s/ Lixue Yang*** |
|  |  | Lixue Yang |
|  |  | Chief Executive Officer, President, Secretary, Treasurer, Director |

---

&nbsp;&nbsp;&nbsp;&nbsp;

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION**

I, Lixue Yang, certify that:

1. I have reviewed this quarterly report on Form 10-Q of QLY BIOTECH GROUP CORP. (the "Company") for the period ending November 30, 2022;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: January 13, 2023 | By: | ***/s/ Lixue Yang*** |
|  |  | Lixue Yang |
|  |  | Chief Executive Officer, President, Secretary, Treasurer, Director |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly Report of QLY BIOTECH GROUP CORP. (the "Company") on Form 10-Q for the period ending November 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), The undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: January 13, 2023 | By: | ***/s/ Lixue Yang*** |
|  |  | Lixue Yang |
|  |  | Chief Executive Officer, President, Secretary,<br> Treasurer, Director |

---

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.